translation agency

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update
Fat-Bubble Drugs Near Approval

July 5, 1995
Washington Post (Health) (07/04/95) P. 15

An advisory panel to the U.S. Food and Drug Administration has recommended approval of two experimental drugs made of fat bubbles for the treatment of Kaposi's sarcoma (KS). Scientists believe that the fat coating--made up of liposomes, or microscopic fat bubbles used to coat highly toxic medicines --allows the drugs to travel to site of the disease without spreading into other cells and poisoning them along the way. This method permits more of a drug to be delivered without severe side effects. The two drugs receiving tentative approval from the committee were NeXstar Pharmaceuticals Inc.'s DaunoXome and Liposome Technology Inc.'s Dox-SL, which was recommended under certain conditions. A study of more than 200 advanced KS patients found that those who received DaunoXome lived one year, while those on standard therapy lived 26 fewer days. More importantly, DaunoXome patients had 10 times fewer side effects than other patients, NeXstar officials said.